Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. / Moreira, José Manuel Alfonso; Ohlsson, Gita; Gromov, Pavel; Simon, Ronald; Sauter, Guido; Celis, Julio E; Gromova, Irina.

In: Molecular & Cellular Proteomics, Vol. 9, No. 1, 2010, p. 161-77.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Moreira, JMA, Ohlsson, G, Gromov, P, Simon, R, Sauter, G, Celis, JE & Gromova, I 2010, 'Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer', Molecular & Cellular Proteomics, vol. 9, no. 1, pp. 161-77. https://doi.org/10.1074/mcp.M900294-MCP200

APA

Moreira, J. M. A., Ohlsson, G., Gromov, P., Simon, R., Sauter, G., Celis, J. E., & Gromova, I. (2010). Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Molecular & Cellular Proteomics, 9(1), 161-77. https://doi.org/10.1074/mcp.M900294-MCP200

Vancouver

Moreira JMA, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE et al. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Molecular & Cellular Proteomics. 2010;9(1):161-77. https://doi.org/10.1074/mcp.M900294-MCP200

Author

Moreira, José Manuel Alfonso ; Ohlsson, Gita ; Gromov, Pavel ; Simon, Ronald ; Sauter, Guido ; Celis, Julio E ; Gromova, Irina. / Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. In: Molecular & Cellular Proteomics. 2010 ; Vol. 9, No. 1. pp. 161-77.

Bibtex

@article{a2e828620c234f869e2ddf181a5110e2,
title = "Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer",
abstract = "It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.",
keywords = "Animals, Binding Sites, Blotting, Western, COS Cells, Cercopithecus aethiops, Electrophoresis, Gel, Two-Dimensional, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Membrane Proteins, Neoplasm Proteins, Phosphorylation, Prognosis, Proteomics, Tissue Array Analysis, Tumor Markers, Biological, Urinary Bladder Neoplasms",
author = "Moreira, {Jos{\'e} Manuel Alfonso} and Gita Ohlsson and Pavel Gromov and Ronald Simon and Guido Sauter and Celis, {Julio E} and Irina Gromova",
year = "2010",
doi = "10.1074/mcp.M900294-MCP200",
language = "English",
volume = "9",
pages = "161--77",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology",
number = "1",

}

RIS

TY - JOUR

T1 - Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer

AU - Moreira, José Manuel Alfonso

AU - Ohlsson, Gita

AU - Gromov, Pavel

AU - Simon, Ronald

AU - Sauter, Guido

AU - Celis, Julio E

AU - Gromova, Irina

PY - 2010

Y1 - 2010

N2 - It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.

AB - It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.

KW - Animals

KW - Binding Sites

KW - Blotting, Western

KW - COS Cells

KW - Cercopithecus aethiops

KW - Electrophoresis, Gel, Two-Dimensional

KW - Genetic Predisposition to Disease

KW - Humans

KW - Immunohistochemistry

KW - Membrane Proteins

KW - Neoplasm Proteins

KW - Phosphorylation

KW - Prognosis

KW - Proteomics

KW - Tissue Array Analysis

KW - Tumor Markers, Biological

KW - Urinary Bladder Neoplasms

U2 - 10.1074/mcp.M900294-MCP200

DO - 10.1074/mcp.M900294-MCP200

M3 - Journal article

C2 - 19783793

VL - 9

SP - 161

EP - 177

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 1

ER -

ID: 41043370